Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5199482
Max Phase: Preclinical
Molecular Formula: C35H57F3N10O8
Molecular Weight: 688.88
Associated Items:
ID: ALA5199482
Max Phase: Preclinical
Molecular Formula: C35H57F3N10O8
Molecular Weight: 688.88
Associated Items:
Canonical SMILES: CC(C)C[C@H]1NC(=O)[C@H](NC(=N)N)CCOCNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)Cc2cccc(c2)CNC1=O.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C33H56N10O6.C2HF3O2/c1-21(2)16-27-30(46)38-19-23-9-7-8-22(17-23)18-28(44)40-25(11-4-6-14-35)31(47)41-24(10-3-5-13-34)29(45)39-20-49-15-12-26(32(48)42-27)43-33(36)37;3-2(4,5)1(6)7/h7-9,17,21,24-27H,3-6,10-16,18-20,34-35H2,1-2H3,(H,38,46)(H,39,45)(H,40,44)(H,41,47)(H,42,48)(H4,36,37,43);(H,6,7)/t24-,25-,26+,27+;/m0./s1
Standard InChI Key: YQFXAHYFHBKNQZ-GHXHZZECSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 688.88 | Molecular Weight (Monoisotopic): 688.4384 | AlogP: -1.05 | #Rotatable Bonds: 11 |
Polar Surface Area: 268.67 | Molecular Species: BASE | HBA: 9 | HBD: 10 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.72 | CX Basic pKa: 11.04 | CX LogP: -2.26 | CX LogD: -9.34 |
Aromatic Rings: 1 | Heavy Atoms: 49 | QED Weighted: 0.08 | Np Likeness Score: 0.99 |
1. Huber S, Braun NJ, Schmacke LC, Quek JP, Murra R, Bender D, Hildt E, Luo D, Heine A, Steinmetzer T.. (2022) Structure-Based Optimization and Characterization of Macrocyclic Zika Virus NS2B-NS3 Protease Inhibitors., 65 (9.0): [PMID:35475620] [10.1021/acs.jmedchem.1c01860] |
Source(1):